Pomalidomide shows significant therapeutic activity against CNS lymphoma with a major impact on the tumor microenvironment in murine models.

Pomalidomide shows significant therapeutic activity against CNS lymphoma with a major impact on the tumor microenvironment in murine models.

Primary CNS lymphoma carries a poor prognosis. Novel therapeutic agents are urgently needed. Pomalidomide (POM) is a novel immunomodulatory drug with anti-lymphoma activity. CNS pharmacokinetic analysis was performed in rats to assess the CNS penetration of POM. Preclinical evaluation of POM was per...

Full description

Bibliographic Details
Main Authors: Zhimin Li, Yushi Qiu, David Personett, Peng Huang, Brandy Edenfield, Jason Katz, Darius Babusis, Yang Tang, Michael A Shirely, Mehran F Moghaddam, John A Copland, Han W Tun
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3734315?pdf=render

Internet

http://europepmc.org/articles/PMC3734315?pdf=render

Similar Items